AR075245A1 - Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen. - Google Patents
Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen.Info
- Publication number
- AR075245A1 AR075245A1 ARP100100313A ARP100100313A AR075245A1 AR 075245 A1 AR075245 A1 AR 075245A1 AR P100100313 A ARP100100313 A AR P100100313A AR P100100313 A ARP100100313 A AR P100100313A AR 075245 A1 AR075245 A1 AR 075245A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hydrogen atom
- lower alkyl
- halogen
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto fenilimidazol representado por la formula general (1) en donde R1 representa un átomo de hidrogeno, un grupo fenilalquilo inferior o un grupo piridilalquilo inferior, y el anillo de benceno y el anillo piridino se sustituyen opcionalmente con 1 o 2 sustituyentes seleccionados del grupo que consiste de átomos de halogeno, grupos ciano y grupos alquilo inferior sustituidos por halogeno. Uno de R2 y R3 representa un átomo de hidrogeno y el otro representa un grupo alquilo inferior, R4 representa un grupo alquilo inferior, un grupo furilo, un grupo tienilo o un grupo fenilo opcionalmente sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste de grupos alquilo inferior, grupos alcoxi inferior, átomos de halogeno, grupo carboxilo, grupos alcoxicarbonilo inferior y grupos alquilo inferior sustituidos por halogeno; R5 y R6 son iguales o diferentes, y representan un átomo de hidrogeno o un grupo alquilo inferior, R7 y R8 son iguales o diferentes, y representan un átomo de hidrogeno o un grupo alcoxi inferior. Sin embargo, cuando R1 representa un grupo fenilalquilo inferior no sustituido, R2 representa un grupo alcoxi inferior, R3 representa un átomo de hidrogeno, R4 representa un grupo fenilo no sustituido o un grupo fenilo que tiene 1 o 2 grupos alquilo inferiores sustituidos por halogeno y R5 representa un átomo de hidrogeno, R6 no es un átomo de hidrogeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009023793 | 2009-02-04 | ||
| JP2009255980 | 2009-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075245A1 true AR075245A1 (es) | 2011-03-16 |
Family
ID=42542093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100313A AR075245A1 (es) | 2009-02-04 | 2010-02-04 | Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8329739B2 (es) |
| EP (1) | EP2394996B8 (es) |
| JP (1) | JP5540227B2 (es) |
| KR (1) | KR101676889B1 (es) |
| CN (1) | CN102307861B (es) |
| AR (1) | AR075245A1 (es) |
| AU (1) | AU2010211753B2 (es) |
| BR (1) | BRPI1007902B1 (es) |
| CA (1) | CA2750704C (es) |
| DK (1) | DK2394996T3 (es) |
| ES (1) | ES2587942T3 (es) |
| HK (1) | HK1160123A1 (es) |
| HU (1) | HUE028840T2 (es) |
| MX (1) | MX2011008197A (es) |
| MY (1) | MY156539A (es) |
| PL (1) | PL2394996T3 (es) |
| PT (1) | PT2394996T (es) |
| RU (1) | RU2497811C2 (es) |
| SG (1) | SG172895A1 (es) |
| TW (1) | TWI435871B (es) |
| WO (1) | WO2010090200A1 (es) |
| ZA (1) | ZA201104932B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2280706T3 (pl) * | 2008-05-14 | 2013-05-31 | Otsuka Pharma Factory Inc | Kompozycje zawierające pochodne benzenu aktywujące lipazę lipoproteinową |
| ES2677356T3 (es) | 2010-03-24 | 2018-08-01 | Amitech Therapeutics Solutions, Inc. | Compuestos heterocíclicos útiles para la inhibición de quinasas |
| SG11201705013QA (en) * | 2014-12-19 | 2017-07-28 | Galderma Res & Dev | Novel compounds, synthesis method thereof and use of same in medicine and in cosmetics |
| HUE058875T2 (hu) * | 2015-12-25 | 2022-09-28 | Otsuka Pharma Factory Inc | Fenilimidazol vegyület |
| CN106946862B (zh) * | 2017-03-31 | 2019-09-03 | 枣庄学院 | 1-烷烃-6-甲基-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI57407C (fi) * | 1971-05-11 | 1980-08-11 | Ciba Geigy Ag | Analogifoerfarande foer framstaellning av nya farmakologiskt verksamma i 2-staellningen substituerade 4(5)-pyridyl-5(4)-fenyl-imidazoler |
| DE3411997A1 (de) | 1984-03-31 | 1985-10-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue redox-indikatoren |
| JP2001226358A (ja) | 1999-10-12 | 2001-08-21 | Japan Tobacco Inc | Ｌｐｌ活性増強剤 |
| WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
| PL2280706T3 (pl) | 2008-05-14 | 2013-05-31 | Otsuka Pharma Factory Inc | Kompozycje zawierające pochodne benzenu aktywujące lipazę lipoproteinową |
-
2010
- 2010-02-03 US US13/145,041 patent/US8329739B2/en active Active
- 2010-02-03 BR BRPI1007902-5A patent/BRPI1007902B1/pt active IP Right Grant
- 2010-02-03 JP JP2010549482A patent/JP5540227B2/ja active Active
- 2010-02-03 ES ES10738531.2T patent/ES2587942T3/es active Active
- 2010-02-03 EP EP10738531.2A patent/EP2394996B8/en active Active
- 2010-02-03 MY MYPI2011003582A patent/MY156539A/en unknown
- 2010-02-03 MX MX2011008197A patent/MX2011008197A/es active IP Right Grant
- 2010-02-03 HU HUE10738531A patent/HUE028840T2/en unknown
- 2010-02-03 AU AU2010211753A patent/AU2010211753B2/en active Active
- 2010-02-03 WO PCT/JP2010/051469 patent/WO2010090200A1/ja active Application Filing
- 2010-02-03 KR KR1020117018550A patent/KR101676889B1/ko active IP Right Grant
- 2010-02-03 TW TW099103198A patent/TWI435871B/zh active
- 2010-02-03 SG SG2011049533A patent/SG172895A1/en unknown
- 2010-02-03 PT PT107385312T patent/PT2394996T/pt unknown
- 2010-02-03 DK DK10738531.2T patent/DK2394996T3/en active
- 2010-02-03 CN CN201080006527.5A patent/CN102307861B/zh active Active
- 2010-02-03 PL PL10738531.2T patent/PL2394996T3/pl unknown
- 2010-02-03 RU RU2011136719/04A patent/RU2497811C2/ru active
- 2010-02-03 CA CA2750704A patent/CA2750704C/en active Active
- 2010-02-04 AR ARP100100313A patent/AR075245A1/es not_active Application Discontinuation
-
2011
- 2011-05-05 ZA ZA2011/04932A patent/ZA201104932B/en unknown
-
2012
- 2012-01-18 HK HK12100568.8A patent/HK1160123A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110275823A1 (en) | 2011-11-10 |
| TW201033179A (en) | 2010-09-16 |
| US8329739B2 (en) | 2012-12-11 |
| JP5540227B2 (ja) | 2014-07-02 |
| KR20110111300A (ko) | 2011-10-10 |
| PT2394996T (pt) | 2016-08-31 |
| HUE028840T2 (en) | 2017-01-30 |
| KR101676889B1 (ko) | 2016-11-16 |
| CA2750704C (en) | 2016-11-22 |
| HK1160123A1 (zh) | 2012-08-10 |
| EP2394996B8 (en) | 2016-10-19 |
| ZA201104932B (en) | 2012-09-26 |
| MX2011008197A (es) | 2011-08-17 |
| MY156539A (en) | 2016-02-26 |
| EP2394996A4 (en) | 2012-09-12 |
| RU2497811C2 (ru) | 2013-11-10 |
| CN102307861A (zh) | 2012-01-04 |
| PL2394996T3 (pl) | 2016-12-30 |
| SG172895A1 (en) | 2011-08-29 |
| DK2394996T3 (en) | 2016-08-01 |
| ES2587942T3 (es) | 2016-10-27 |
| JPWO2010090200A1 (ja) | 2012-08-09 |
| EP2394996A1 (en) | 2011-12-14 |
| CA2750704A1 (en) | 2010-08-12 |
| AU2010211753B2 (en) | 2015-11-05 |
| BRPI1007902B1 (pt) | 2022-01-04 |
| CN102307861B (zh) | 2014-10-29 |
| AU2010211753A1 (en) | 2011-07-28 |
| BRPI1007902A2 (pt) | 2020-08-18 |
| WO2010090200A1 (ja) | 2010-08-12 |
| RU2011136719A (ru) | 2013-03-10 |
| TWI435871B (zh) | 2014-05-01 |
| EP2394996B1 (en) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000061A (es) | Compuestos de pirrol | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| CY1120477T1 (el) | Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| PE20110397A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| MX2010004893A (es) | Compuesto heterociclico y composicion farmaceutica del mismo. | |
| CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| AR075245A1 (es) | Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen. | |
| ECSP109958A (es) | Derivados de pirimidina 934 | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| AR113842A1 (es) | Derivados de tiazol microbiocidas | |
| CO6460726A2 (es) | Derivado de 5-hidroxi-pirimidin-4-carboxamida | |
| DK2197860T3 (da) | Nye forbindelser som adenosin-A1-receptorantagonister | |
| CO6160310A2 (es) | Nuevos derivados imidazolonas su preparacion como medicamentos composiciones farmaceuticas utilizacion como inhibidores de proteinas quinasas principalmente cdc7 | |
| AR066603A1 (es) | Derivados de arilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |